These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 7481868)

  • 1. Intraperitoneal paclitaxel in the management of ovarian cancer.
    Markman M
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):86-7. PubMed ID: 7481868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer?
    Markman M; Francis P; Rowinsky E; Hoskins W
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):84-7. PubMed ID: 7597437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboplatin versus cisplatin in ovarian cancer.
    Alberts DS
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal administration of Taxol in the management of ovarian cancer.
    Markman M; Rowinsky E; Hakes T; Reichman B; Jones W; Lewis JL; Rubin S; Curtin J; Barakat R; Almadrones L
    J Natl Cancer Inst Monogr; 1993; (15):103-6. PubMed ID: 7912515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.
    Ozols RF
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):1-6. PubMed ID: 8643963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel and carboplatin for advanced breast cancer.
    Perez EA; Hartmann LC
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):41-5. PubMed ID: 8893899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of paclitaxel in the treatment of breast cancer: the American Cooperative Group Experience.
    Sledge GW
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):10-2. PubMed ID: 8629029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxol: an important new drug in the management of epithelial ovarian cancer.
    Markman M
    Yale J Biol Med; 1991; 64(6):583-90. PubMed ID: 1687343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel plus carboplatin in the treatment of ovarian cancer.
    Ozols RF
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):84-9. PubMed ID: 10190787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status and future directions of platinum/paclitaxel-based chemotherapy of ovarian cancer.
    Markman M
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-24-S11-27. PubMed ID: 9314295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy of advanced ovarian cancer: current status and future directions.
    Ozols RF; Vermorken JB
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-1-S2-9. PubMed ID: 9045324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience.
    Thigpen T; Vance RB; McGuire WP; Hoskins WJ; Brady M
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):23-31. PubMed ID: 8553080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly paclitaxel in the management of ovarian cancer.
    Markman M
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):37-40. PubMed ID: 10952125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
    Armstrong DK; Fleming GF; Markman M; Bailey HH
    Gynecol Oncol; 2006 Nov; 103(2):391-6. PubMed ID: 16626792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.